

JAN 0 3 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Spplication of:

Jenny Louie-HELM et al.

Confirmation No.: 1055

Serial No.: 10/014,750

Group Art Unit: 1618

Filing Date: October 25, 2001

Examiner: Blessing M. FUBARA

Title: FORMULATION OF AN ERODIBLE, GASTRIC RETENTIVE ORAL DOSAGE FORM

USING IN VITRO DISINTEGRATION TEST DATA

AMENDMENT UNDER 37 C.F.R. § 1.111

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Madame:

Responsive to the non-final Office Action mailed on September 27, 2005, please reconsider this application in view of the amendments and remarks set forth in this paper. As this paper is timely filed within the three-month shortened statutory period for response, no fee accompanies this paper. Filed with this paper is an Information Disclosure Statement (and fee).

AMENDMENTS TO THE CLAIMS:

The amendments to the claims are reflected in the listing of the claims set forth on page 2 to 8 of this paper.

REMARKS:

Applicants' comments in support of this application are presented in the remarks set forth on pages 9 to 11 of this paper.

01/04/2006 HDESTA1 00000052 10014750

01 FC:2202

25.00 OP